Business
Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation
SEATTLE, Wash and VANCOUVER, British Columbia, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical
About this update from Achieve Life Sciences, Inc.
[{"type":"text","content":"SEATTLE, Wash and VANCOUVER, British Columbia, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,459,328 covering the mesylate salt formulation of cytisinicline and the process for its development. “Continuing to expand our intellectual patent portfolio around cytisinicline further protects our nicotine dependence franchise,” commented John Bencich, Chief Executive Officer of Achieve. “Including this latest issuance, our family of patents protecting cytisinicline is now 18, including exclusivity until 2040 for the novel 3.0 mg, three-times daily dosing regimen that has been shown to be effective and very well-tolerated in our Phase 3 clinical development program.” Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. Achieve continues to pursue numerous patents that will further enhance the product’s stability and the potential for life cycle expansion via varying methods of administration. Achieve is currently conducting the final FDA-registration enabling Phase 3 ORCA-3 trial for smoking cessation and the Phase 2 ORCA-V1 trial evaluating cytisinicline for e-cigarette cessation. The Company continues to expect topline data results for both trials to be announced in the second quarter of 2023. For more information on Achieve Life Sciences and cytisinicline please visit www.achievelifesciences.com. About Achieve and Cytisinicline Achieve’s focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline. Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually.1,2 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.2 In addition, there are nearly 11 million adults in the United States who use e-cigarettes, also known as vaping.3 While nicotine e-ci...